Author name: Professor Paul Knoepfler, Ph.D.

Paul Knoepfler, Ph.D. is a Professor at UC Davis School of Medicine in Cell Biology and Human Anatomy. His lab does research on stem cells and cancer, especially from an epigenomic angle. He also has been working on policy and ethics matters for many years. The author of 3 books, he also has a popular TED talk on designer babies.

Weekly reads: cartilage regeneration, ferroptosis, Aspen Neuroscience raises $115M, more on rare diseases

stem cell therapy for knees arthritis, cartilage regeneration

Cartilage regeneration has been a holy grail for the stem cell field for decades. It has mostly been just out of reach though. Even most unproven stem cell clinics have stopped claiming to regrow cartilage in joints. For instance, a typical clinic that now injects PRP or cells into arthritic knees doesn’t claim to regrow […]

Weekly reads: cartilage regeneration, ferroptosis, Aspen Neuroscience raises $115M, more on rare diseases Read More »

Nucleus Genomics faces criticism as it and other firms promise embryo optimization despite unresolved scientific, ethical questions

Nucleus Genomics

A new wave of startups like Nucleus Genomics is promising genetically ‘optimized’ future children. However, the science and ethics remain murky. These firms are marketing the idea of selecting traits for customers’ future babies through genetic screening based on elective IVF. Nucleus is also specifically facing criticism now. Elective IVF What exactly is elective IVF?

Nucleus Genomics faces criticism as it and other firms promise embryo optimization despite unresolved scientific, ethical questions Read More »

Weekly reads: FDA approves peptide therapy for Barth, other rare disease news, induced totipotency

peptide therapy, Barth Syndrome

When I mention rare diseases what do you think of first and same question when I say “peptide therapy”? I don’t typically think of these together, but a new FDA approval unites them. The agency recently gave accelerated approval for a peptide therapy for Barth Syndrome. Let’s go through this first. FDA, rare diseases, &

Weekly reads: FDA approves peptide therapy for Barth, other rare disease news, induced totipotency Read More »

Khloé & Kim Kardashian stem cell adventures in Mexico, MUSE cells raise concerns

In the past, when people have asked about Kim Kardashian stem cell treatments, they usually meant those vampire facelifts she did years ago. It’s hard to forget the blood-smeared face. However, that’s not really a stem cell treatment. It’s good that Kim later expressed regrets about vampire facelifts due to the pain involved. From a

Khloé & Kim Kardashian stem cell adventures in Mexico, MUSE cells raise concerns Read More »

Weekly reads: MAHA summit, Ittleman on FL stem cell law, NYT on brain organoids, Dr. BS

MAHA Summit

There was a MAHA summit this week that raised several potential concerns for me. Let’s start there. Then we’ll go into the rest of the week’s news and research related to the regenerative medicine and stem cell field. MAHA summit: peptides, compounding, and more When I first heard there was going to be a MAHA

Weekly reads: MAHA summit, Ittleman on FL stem cell law, NYT on brain organoids, Dr. BS Read More »

More red flags on peptides even as softening of FDA oversight could happen soon under RFK Jr.

peptides scam, peptides

Last year, HHS Secretary RFK Jr. claimed in a post that the FDA was suppressing things like peptides and stem cells. I started hearing about “peptides” earlier, about 2-3 years ago. Some were saying that specific peptides were even better than stem cells, which is a big red flag. The term “peptides” in this context

More red flags on peptides even as softening of FDA oversight could happen soon under RFK Jr. Read More »

Weekly reads: new MSCs for heart disease pub already under fire, Google’s new h-index, Tidmarsh out, alleged cord blood banking scam

MSCs for heart disease

The idea of mesenchymal stromal/stem cells or MSCs for heart disease has been around a long time. It never seemed to make much sense to me though. The broader stem cells for heart disease sub-field of regenerative medicine also has had problems over the years. A new BMJ paper reports a supposed major benefit of

Weekly reads: new MSCs for heart disease pub already under fire, Google’s new h-index, Tidmarsh out, alleged cord blood banking scam Read More »

Recommended reads: Valentina Greco, CRISPR trials halted on safety, JAX acquisition, Prasad vs. CBER

Vinay Prasad

It seems like there’s still chaos inside the FDA’s biologics branch CBER led by Vinay Prasad. As many of you will remember, Prasad was forced out shortly after becoming CBER Director earlier this year. Then Makary and RFK Jr. pushed successfully to bring him back. Since then apparently things have not been great between Prasad

Recommended reads: Valentina Greco, CRISPR trials halted on safety, JAX acquisition, Prasad vs. CBER Read More »

Stem cell therapy cost goes up & what to consider looking ahead

stem cell therapy cost

How much does stem cell therapy cost in late 2025? How have prices changed from past years? To authoritatively answer these questions now, we need data along with expert perspectives. I’ve been tracking stem cell treatment cost for about a decade now. Some surprises emerged in a new analysis I did on the current cost

Stem cell therapy cost goes up & what to consider looking ahead Read More »

Weekly reads: FDA warnings on immunotherapy toothpaste & exosomes, upbeat SCID work, animal model alternatives

Reisacher, Allerdent

Did you know there’s immunotherapy toothpaste? It’s intended to provide immunotherapy of a kind while you brush. Some of this is meant to help allergies so the products can also be called allergenic toothpastes. Let’s start this week’s recommended reads with a warning from the FDA here. Immunotherapy toothpaste Allerdent I became aware of this

Weekly reads: FDA warnings on immunotherapy toothpaste & exosomes, upbeat SCID work, animal model alternatives Read More »